Endocrine Peptides Test Market size in terms of volume and value 2017 - 2027

Endocrine peptide test is used for the measurement of the level of c-peptide present in the blood. C-peptide and insulin are usually found in equivalent amounts. Insulin aids the body to use and regulate the quantity of glucose present in the blood. The level of c-peptide present in the blood can indicate the amount of insulin made by pancreas. Sugar level in the body does not affect by the C-peptide. C-peptide is also called the connecting peptide. It is a short 31-amino acid polypeptide. Endocrine peptide test can be done when diabetes is just been initiate and it is not clear whether type 1or type 2 diabetes is present. The test is basically performed to check the type of diabetes present in the body. C-peptide is produced in same amount to insulin. Both c-peptide and insulin are secreted out by the pancreas at the same time and in same quantity. C-peptide is also called as connecting peptide and it is a short 31-amino acid polypeptide. In the pro insulin molecule endocrine peptide connects insulin's A- chain to its B-chain. It allows the glucose to enter the body cells where it is used for energy .A measurement of c- peptide blood serum level can be used to distinguish between certain diseases with similar clinical features. The test is basically performed to check the type of diabetes present in the body. This is performed in those patients who are confirmed to have diabetes but are not able to find whether it is type-1or type-2 i.e. diabetes mellitus or diabetes insipedus .The test is also performed to find the cause of blood sugar (hyperglycemia) or a non-cancerous growth (tumor) in the pancreas (insulinoma).

Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5275

Endocrine Peptides Test Market: Drivers and Restraints

The endocrine peptides test market is increasing due to the increasing prevalence of endocrine disorders like thyroid disorders, diabetes, infertility, etc. In addition, the decreased immunity and higher risk of developing complications are also some of the factors driving the growth of global endocrine peptides test market. Technological advancement in terms of accuracy and affordability resulted in an increased usage of these tests. Testing has raised the demand, helping the market to grow.

Endocrine Peptides Test Market: Segmentation

Tentatively, global endocrine peptides test market has been segmented on the basis of test type, end user, and geography.

Based on test type, global endocrine peptides test market is segmented as below:

Estradiol (E2)

Dehydroepiandrosterone sulfate (DHEAS)

Human Chorionic Gonadotropin (hCG)

Progesterone, Luteinizing Hormone (LH)

Thyroid Stimulating Hormone (TSH)

thyroid prolactin

Others

Based on end user, global endocrine peptides test market is segmented as below:

Hospitals

Physicians’ offices

Commercial laboratories

Health care centers

Endocrine Peptides Test Market: Overview

Request For Table Of Content @ https://www.futuremarketinsights.com/toc/rep-gb-5275

Based on the test type, the global endocrine peptides market is segmented into Estradiol (E2), Dehydroepiandrosterone sulfate (DHEAS), Human Chorionic Gonadotropin (hCG), Progesterone, Luteinizing Hormone (LH), Thyroid Stimulating Hormone (TSH), thyroid prolactin and others. Thyroid Stimulating hormone (TSH) attributed to the growing occurrences of TSH-related disorders and the increasing awareness about the correlation between variations in the thyroid hormones levels and cardiovascular disorders. Similarly based on end user, the global endocrine peptides market is segmented into hospitals, physician’s offices, commercial laboratories and health care centers. Amongst them hospitals are the major users for the endocrine peptides test.

Endocrine Peptides Test Market: Regional Outlook

Geographically, global endocrine peptides test market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America is expected to dominate global endocrine peptides test market over the forecast period due to high prevalence of endocrine disorders. Western Europe is expected to be the second largest market for endocrine peptides test. Asia Pacific market is expected to experience delayed growth due to unawareness and low disposable income.

Endocrine Peptides Test Market: Key Players

Some of the players identified in global endocrine peptides test are Quest Diagnostics, Siemens Healthcare, Abbott Laboratories, bioMerieux and others.

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.